@article {1667,
	title = {Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL.},
	journal = {Invest New Drugs},
	volume = {30},
	year = {2012},
	month = {2012 Apr},
	pages = {828-32},
	abstract = {<p>To improve the pharmacokinetic profile of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) an N-terminal specific pegylation was performed to generate pegylated TRAIL (PEG-TRAIL). In in vitro experiments, we found that although PEG-TRAIL was slightly less efficient than recombinant TRAIL in promoting leukemic cell apoptosis, it showed an improved ability to promote migration of bone-marrow mesenchymal stem cells and to elicit the ERK1/2 intracellular signal transduction pathway. Overall, these data suggest that TRAIL pegylation retains, or even enhances, the biological activities of TRAIL relevant for its therapeutic applications.</p>},
	keywords = {Antineoplastic Agents, Apoptosis, Caspase 3, Cell Movement, Dose-Response Relationship, Drug, HL-60 Cells, Humans, Leukemia, Mesenchymal Stromal Cells, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Phosphorylation, Polyethylene Glycols, Recombinant Fusion Proteins, Signal Transduction, Time Factors, TNF-Related Apoptosis-Inducing Ligand},
	issn = {1573-0646},
	doi = {10.1007/s10637-010-9599-8},
	author = {Gonelli, Arianna and Radillo, Oriano and Drioli, Sara and Rimondi, Erika and Secchiero, Paola and Maria Bonora, Gian}
}
